pipette
ESEspañol

Clinical validation of whole-genome and transcriptome sequencing for genetic diagnostics in adult and pediatric AML

A. Staffas, L. Cavelier, K. Olde, C. Orsmark-Pietras, T. Pandzic, I. Golovleva, L. Olsson-Arvidsson, A. Krstic, S. Pradhananga, N. Hollfelder, K. Maqbool, M. Johansson, P. Baliakas, L. Saft, V. Lazarevic, M. Jädersten, S. Deneberg, A. Robelius, M. Höglund, G. Orrsjö, J. Abrahamsson, C. J. Pronk, J. Palle, H. Vogt, K. Belander-Stralin, U. Noren-Nyström, L. Palmqvist, V. Wirta, G. Barbany, T. Fioretos, L. Fogelstrand, R. Rosenquist

PreprintReal-world use

In the authors' words

Diagnosis and risk stratification of acute myeloid leukemia (AML) rely on the detection of diverse genetic aberrations using multiple standard-of-care (SoC) assays. With the increasing number of clinically relevant alterations and limited resolution of SoC methods, whole-genome and transcriptome sequencing (WGTS) represents a promising alternative. In this multi-center study, we evaluated the technical feasibility and clinical performance of WGTS across five sites in Sweden by comparison with SoC diagnostics. A total of 235 patients (197 adults and 38 children) underwent parallel SoC testing and WGTS analysis. WGTS identified 57/58 (98%) clinically relevant gene rearrangements detected by SoC and revealed an additional 12 rearrangements, including RUNX1::RUNX1T1, KMT2A and NUP98 rearrangements. For structural variants and copy-number variants, WGS showed 90% concordance with SoC, with discrepancies mainly involving subclonal events or tetraploidy. For gene mutations, WGS achieved 94% sensitivity, detecting all NPM1, CEBPA bZIP, and IDH1/2 mutations, but missing low-frequency FLT3-ITDs. Tumor-only analysis performed comparably to paired analysis for clinically relevant variants. Diagnostic classification was highly concordant between WGTS and SoC (WHO: 94%; ICC: 93%), with improved genetic subclassification in 5 - 6% of cases by WGTS. ELN risk stratification was concordant in 97% with WGTS reclassifying 2% of patients. Finally, a ring trial involving seven cases demonstrated complete agreement across sites in identifying aberrations. In conclusion, WGTS is a feasible and accurate comprehensive diagnostic approach for AML in a decentralized setting, improving detection of clinically relevant aberrations. However, complementary high-sensitivity assays for FLT3-ITD remain necessary for routine clinical implementation.

Main resultLimitation the authors admit

Appeared: Thursday, November 19. medRxiv. Preprint, not yet peer-reviewed.

DOI: 10.64898/2026.11.16.26367955